GMDA - Gamida cell therapy Omisirge for blood cancer patients approved by FDA
2023-04-17 13:51:18 ET
- The US FDA has approved Omisirge (omidubicel-onlv), an allogeneic blood-based cell therapy from Gamida Cell Ltd. ( NASDAQ: GMDA ) for patients with blood cancers to be used before umbilical cord blood transplants.
- The stock is up 34% in Monday afternoon trading.
- The therapy is designed to hasten the production of neutrophils, a type of white blood cells as well as reduce the risk of infection.
- Stem cell transplant is routinely used as treatment for those with blood cancers. Prior to the transplant, the patient's own stem cells are removed and may include chemotherapy or radiation, which can weaken the body's immune system.
- Omisirge is given as a single IV dose .
- The treatment's efficacy was demonstrated in a study where those who were given Omisirge saw quicker neutrophil recovery and fewer infections compared to those who didn't receive it.
For further details see:
Gamida cell therapy Omisirge for blood cancer patients approved by FDA